Quick Facts
LambdaVision has raised $7 million in seed funding co-led by Seven Seven Six and Aurelia Foundry Fund to advance its protein-based artificial retina technology.
The Connecticut-based biotech develops a microgravity-enabled artificial retina designed to restore vision for patients with Retinitis Pigmentosa and Age-Related Macular Degeneration.
Its protein film, made of light-sensitive bacteriorhodopsin, is produced aboard the International Space Station to achieve superior structural precision and performance.
The startup has already secured over $15 million in non-dilutive funding from NASA, the National Eye Institute, and the National Science Foundation.
Funds from this round will be used to scale production, progress preclinical development, and prepare for Series A investment.
LambdaVision was founded by CEO Dr. Nicole Wagner, with the goal of leveraging space manufacturing for next-generation vision therapies.
The company sees its innovation as a foundation for future biotechnology manufacturing in orbit, enabling precise therapeutic assembly beyond Earth-based limits.